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Flavonoids are a group of low molecular weight plant products, ba-
sed on the parent compound, flavone (2-phenylchromone) and have
shown potential for application in a variety of pharmacological tar-
gets. By using random screening techniques flavones have been
proposed as inhibitors of aldose reductase, an enzyme crucial in
the treatment of diabetic complications such as cataract formation.
On the other hand, a large number of natural and synthetic flavo-
noids are being tested as specific inhibitors of protein tyrosine ki-
nase (PTK). Kinetic analyses of the PTK inhibition indicate that
flavonoids are competitive inhibitors with respect to the nucleotide
ATP. A thorough investigation of the available experimental data
base by using both classical and quantum chemical descriptors has
been performed in order to develop quantitative structure-activity
relationships for these enzyme systems. Relevance of the descrip-
tors to binding properties of both enzyme receptors active site is
proposed and the obtained results demonstrate in detail which spe-
cific electronic as well as the hydrophobic and steric properties of
the substituents play a significant role in their differential binding.
Key words: QSAR, flavonoid derivatives, aldose reductase, protein
tyrosine kinase.
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INTRODUCTION
Flavonoids are a group of low molecular weight plant products, analogs
of flavone (2-phenylchromone) and have found wide interest as potential
pharmacological agents. Their abundancy, relatively simple availability by
synthetic means and interesting biological activity profiles in several enzy-
matic systems render them attractive for study. By application of random
screening techniques flavones have been proposed as potential inhibitors of
aldose reductase, an enzyme crucial in the treatment of diabetic complica-
tions such as cataract formation.1–4 Using reduced nicotinamide-adenine-
dinucleotide phosphate (NADPH) as a cofactor, aldose reductase (AR) redu-
ces aldose sugars to their alcohols, e.g. glucose to sorbitol, while the second
enzyme, sorbitol dehydrogenase (1-iditol dehydrogenase, EC 1.1.1.14), oxi-
dizes sorbitol to fructose. Under diabetic conditions the glucose level in this
pathway is increased and sorbitol is produced more rapidly than converted
to fructose. The accumulation of sugar alcohols in lens, nerve or retina re-
sults in hyperosmotic effect which leads to lens swelling and subsequent
cataract formation5 as well as the pathologic changes in other tissues. A
possible prevention or treatment of these effects is the inhibition of AR. The
development of aldose reductase inhibitors (ARIs) enabled also the evalua-
tion of role of AR in diabetic complications.
The inhibitory effect on aldose reductase was observed in structurally
diverse compounds tetramethyleneglutaric acid, flavone, chinoline, couma-
rin, xanthone, naphthalene, quinazoline, phthalazine, benzoxazine or rho-
danine derivatives,6–10 which can be divided generally in two groups of
ARIs, those containing a carboxylic acid moiety and those containing rigid
spirohydantoins or related ring systems.11
Kador et al.6,12 have shown that the structural requirements for the in-
hibitory activity consist of a generally planar structure with two aromatic
hydrophobic regions and a common region susceptible to charge-transfer in-
teractions. This observation lead to the proposed structure of AR with the
inhibitor binding site with a hydrophobic (lipophilic) region and a region at
which reversible charge transfer (nucleophilic substitution) can occur. Three
distinct enzyme regions were proposed: a substrate site, nucleotide cofactor
fold and inhibitor site.12
Flavonoids derivatives were found to be more potent than the previously
known ARIs, tetramethyleneglutaric acid or isoquinoline analogs.1 Some
qualitative observations on structural requirements for the inhibitory activ-
ity like the ortho orientation of the hydroxyls in positions 3' and 4' of ring B
were also determined. Further study2 concentrated on the effect of number
of hydroxyls in the flavonoid structure and glycosylation on the AR inhibi-
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tory activity. Through the computer modelling and molecular orbital calcu-
lations the most important electronic and steric features were proposed.6,12
ARIs reversibly interact with AR at an inhibitor site, which appears to be
stereospecific and contains a nucleophilic residue. Kinetic studies1,4,13 indi-
cate that ARIs are not competitive with the substrate or NADPH cofactor.
The presence of the selective lipophilic substituents or groups which could
enhance charge transfer would be expected to result in ARI with better in-
hibitory potency. The presence of 7-OH and 3'-OH groups enhance the inhib-
itory activity of certain flavones. The substitution of 2-phenyl substituents
with a carboxyl group retain the inhibitory activity, what lead to the conclu-
sion that only 4-oxo-4H-chromone ring system appears to be necessary for
the inhibitory activity.6 However, further investigations13 revealed that the
presence of two hydroxyl groups in catechol orientation in ring B (3'-OH and
4'-OH) plays an important role in AR inhibitory activity.
On the other hand flavonoids are particularly interesting in their poten-
tial role as specific inhibitors of protein tyrosine kinase (PTK). Protein tyro-
sine kinases (PTKs) constitute a class of enzymes that provide a central
switching mechanism in cellular signal transduction pathways by cataly-
sing the transfer of the -phosphate of either ATP or GTP to specific tyrosine
residues in certain protein substrates.14,15 These enzymes are important
mediators of normal cellular signal transduction, with PTKs being the in-
tracellular effectors for many growth hormone receptors. The discovery of
activated protein-tyrosine kinases as the product of dominant viral-trans-
forming genes (oncogenes) first established the connection between protein-
tyrosine phosphorylation and cell transformation. There is now substantial
evidence accumulating to suggest that the inappropriate or elevated expres-
sion of these enzymes may also contribute to the transformed state of cells
in many human malignancies.16,17 The importance of PTKs in signal trans-
duction and the association of aberrant PTK expression with proliferative
disorders makes substances which modulate the activity of PTKs attractive
therapeutic agents. Central to the function of all PTKs is the recognition
and binding of a nucleoside triphosphate (usually ATP) and an appropriate
tyrosyl-containing substrate, followed by the ensuing direct transfer of pho-
sphate between the two.18 Nucleoside-based analogs were among the first
agents explored as potential inhibitors of ATP binding to PTKs. A variety of
compounds have been shown to inhibit the function of PTKs in a manner
which is competitive with respect to nucleotide binding, among them a large
number of natural and synthetic flavonoids. Kinetic analyses of the PTK in-
hibition indicated that flavonoids were competitive inhibitors with respect
to the nucleotide ATP.19 Flavones and isoflavones differ in their inhibitory
profiles both in their relative selectivity towards PTKs versus serine/threo-
nine kinases and in their potencies among different PTKs.19 Various syn-
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thetic flavonoid analogs have been prepared20–22 with the goal of the devel-
opment of PTK inhibitors as chemotherapeutic agents.
A central question in application of molecular modelling techniques
which include QSAR approach23–26 is the intriguing possibility to elucidate
the structural features in the given series of molecules which would define
their selective activity towards various enzymatic protein systems. QSAR of
flavonoids for inhibition of cAMP phosphodiesterase were determined27 and
new inhibitors of xantine oxidase were also developed using rational design
approach.28 In our continuing effort29–31 towards this goal we have studied
flavones as protein kinase inhibitors by using classical and quantum chemi-
cal QSAR approaches. A benchmark data set of 104 flavonoid derivatives as
inhibitors of p56lck protein tyrosine kinase has been compiled and artificial
neural network (ANN) approach has been applied30 to find out the struc-
tural requirements of the hitherto unknown enzymatic receptor sites for op-
timal interaction with the flavonoid ligands.
In the present work we carried out a quantum chemical/classical QSAR
study on a similarly exhaustive set of 75 flavonoids and closely related com-
pounds tested as AR inhibitors13,32,33 and the obtained structure-activity re-
lationships of both enzyme systems were compared. We believe that such
studies of enzymatic selectivity based on computed properties could become
increasingly important in the current rapidly forthcoming era of genomics/
proteomics drug discovery.
MATERIALS AND METHODS
Molecular structure and numbering of the substituents in the flavonoid deriva-
tives are represented in Figure 1 and structures of the used flavone derivatives (nat-
ural and synthetic), are summarised in Tables IA and IB, for the AR and PTK en-
zyme systems respectively. The inhibitory effects on enzyme aldose reductase were
measured spectrophotometrically. The reaction was initiated by addition of substrate

















Figure 1. Molecular structure, numbering and list of the different substituents at-
tached to the chromone moiety and phenyl ring of flavonoids in the present study.
and the rate of NADPH oxidation was followed by decrease in absorbance at 390
nm.13,32,33 The biological assay data used in this study for the PTK system are re-
sults of in vitro tests for inhibitory activity against protein-tyrosine kinase p56lck, a
lymphoid cell lineage-specific PTK of the src family which is overexpressed in sev-
eral lymphomas effort20–22 and has been utilised by us previously.29–31
The descriptors set containing both classical parameters and quantum chemical
computed descriptors (Table II) was chosen to describe the main physical forces that
could be instrumental in inhibitor binding to the protein receptor: hydrophobicity,
electronic effects and steric effects. Classical parameters were compiled by standard
procedures from the literature.23 In the asssignment of values of classical parame-
ters on the chromone moiety 6 and 8 substituents were parameterized as »ortho« and
»para« substituents, substituents 5 and 7 as »meta« to the pyrone oxygen, respec-
tively.
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TABLE IA
Molecular structures of flavonoids and analogs (isoflavonoids, coumarins) tested
against AR and used in this studya
R2 R3 R5 R6 R7 R8 R3' R4'
COOH OCH3 OH OH OH OH OH OH
COOCH2CH3 OH OCH3 OCH3 OCH3 OCH3 OCOCH3 OCOCH3






a Rh = rhamnose, Glc = glucose.
TABLE IB
List of substituents on the chromone (R3-R8) and phenyl ring (R3'-R5') part of the
flavonoid scaffold used in the study of inhibition of the enzyme PTKa
R3 R5 R6 R7 R8 R3' R4' R5'
OH OH OH OH OH OH OH OH
COOCH3 OCH3 OCH3 OCH3 OCH3 OCH3 OCH3 OCH3
COOH NH2 NH2 OAc OAc NH2 OBn




a Bn = benzyl, Ac = acetyl.
All quantum chemical parameters were calculated with semiempirical AM1 me-
thod,34 available in the Spartan35 program, using the fully optimised geometry of
each compound in question.
Descriptor selections and corresponding models for quantitative structure-activ-
ity relationships were performed using multiple linear regression methods in the
software package Axum 4.0 for Windows. Cross correlation coefficients were used to
eliminate colinear descriptors. No colinearity greater that  0.40 was permitted for
descriptors in a specific QSAR.
RESULTS AND DISCUSSION
AR Inhibition
The classical and quantum chemical descriptors in the QSAR analysis
were used separately in order to compare these two approaches and provide
us with additional validation that our description of the interactions in the
series of enzyme-inhibitor complexes is justified.
Classical Parameters
Monoparametric correlations were performed and good correlations were
obtained with all three types of interactions of the substituents with the re-
ceptor site hydrophobic properties (), the size of the substituents (MR) and
charge at the phenyl ring region of the flavone molecule (B) (Table IA). The
overall correlation matrices for the selected parameters used in the multiple
regression analyses are shown in Table IIIA.
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TABLE II
Classical and quantum chemical parameters used in QSAR study
classical parameters quantum chemical descriptors
Hansch hydrophobic constant () net atomic charge on the nth atom (n),
Hammett electronic constant for the
meta and para position (m and p)
energies of the highest occupied molec-
ular orbital (HOMO)
Molar refractivity (MR) energies of the lowest unoccupied mo-
lecular orbital (LUMO),
total electron surface density (a)
total electron surface HOMO density
total electron surface LUMO density
total dipole moment ()
the energy barrier of the rotation of
the phenyl ring (rot)
The results of regression analyses for the series of 75 inhibitors descri-
bed above are given in Eq. (1) and could be shown in Table IV.*
log 1/C = – 3.04(1.21)B – 1.66(0.23)B – 0.77(0.23)MRB + 4.3(0.38) (1)
n = 75, r = 0.83, p < 10–7, F = 34.667.
In Figure 2a plot of experimental inhibitory activity versus calculated
activity (regression equation) is given.
Quantum Chemical Descriptors
QSAR studies by using quantum chemical parameters are an attractive
alternative to the classical approach. The topography of all nuclei and elec-
trons in a drug molecule is explicitly involved as well as the energy of their
interaction in a drug-receptor complex and is thus suitable for more detailed
analysis of the partitioning of enzyme-inhibitor interactions. The overall
correlation matrices for the selected parameters used in the multiple regres-
sion analyses are shown in Table IIIB.
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TABLE IIIA




MR B –0.11 0.21 1.00
TABLE IIIB
The same as in Table IIIA for the quantum chemical descriptors
4' 2'–4' a3' a3
4' 1.00
2'–4' 0.06 1.00
a3' –0.04 0.10 1.00
a3 0.14 0.11 0.12 1.00
* Due to large volume of the data in the Table IV it is given in the Supplementary material de-
posited at the Editorial office. This material may be found on the www under http://pubwww.
srce.hr/ccacaa or will be aviable on request from the Editorial office.
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Figure 2. Observed versus calculated inhibitory activity for the data base of 75 flavo-
noid analogs as inhibitors of AR: a) with classical parameters (Eq. (1)): n = 75, r =
0.83, F = 34.667; b) with quantum chemical descriptors (Eq. (2)): n = 75, r = 0.79,
F(2,74) = 21.687.
In Eq. (2) the quantitative structure-activity relationship for the quan-
tum chemical descriptors is given.
log 1/C = – 4.21(1.35)4' + 3.94(0.61)2’–4’ – 6.92(0.9) a3’ –
1.74(0.34) a3’ + 14.05(1.31) (2)
n = 75, r = 0.79 , p < 10–7, F = 21.687.
In Figure 2b this relationship is given as a plot of calculated versus ex-
perimental inhibitory activity.*
PTK Inhibition by Flavonoids
Activity-structure relationships of flavonoids inhibiton of PTK has been
studied in our laboratory previously29–31 using multiple linear regression,
artificial neural network as well as CODESSA approach with ortogonalisa-
tion of descriptors, respectively. Thus, we briefly summarise the main con-
clusions here.
The substituents at the 3' and 4' position of the phenyl ring B should
have electron-donating properties and most probably this part of the flavo-
noid molecule interacts with the catalytic domain of the enzyme, through
hydrogen bonds. The chromone moiety shows the dependence on hydropho-
bic () and electronic parameters such as sum of charges at the chromone
ring atoms C3–C8. The steric hindrance of the substituent at C3 position in
the chromone moiety is also a potency determining factor and a bulky group
in this position has an adverse effect on the bioactivity in the series.
The dependence of inhibitory activity on the parameter C3–C8 in our ca-
se is in accordance with QSAR investigation of flavonoids as inhibitors of cy-
clic AMP phosphodiesterase by J. E. Ferrell et al.36 On the basis of quan-
tum-chemical calculations, they found that there is a resemblance between
the charge distribution of the pyranone ring of the inhibitor molecule and
the pyrimidine ring of cAMP. The fact that flavonoids are competitive inhib-
itors of ATP binding site can now be rationalised by extending this analogy
to the benzo--pyrone part of flavones and the pyrimidine ring of ATP.
The high activity of inhibitors containing amino groups seems to rein-
force the proposition that hydrogen bonding plays an important role in the
mechanism of action of these compounds within the catalytic domain. Signi-
ficantly, all derivatives with 4’-NO2 substituent are inactive. These results
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* Due to large volume of the data in the Table V it is given in the Supplementary material de-
posited at the Editorial office. This material may be found on the www under http://pubwww.
srce.hr/ccacaa or will be aviable on request from the Editorial office.
can be further correlated to investigation of J. C. Wallet et al.,37 who in or-
der to study mechanisms of action of flavones at the molecular level, pre-
pare a complex between a 2’,6’-dimethoxyflavone and orthophosphoric acid.
This was considered to be a simple model of interaction between a flavone
and a more complex biological phosphate such as nucleotide, coenzyme or
DNA and the authors concluded that complexes with phosphate groups in-
volve strong hydrogen bonds.
More recently38 crystal structures of aldose reductase with bound citra-
te, cacodylate and the substrate glucose-6-phosphate were reported. The lo-
cation of negative charges within the active site suggests that the active site
contains an anion binding site which interacts with hydroxyl of the Tyr 48
side chain and N of His 110. Additionally,39 the solved crystal structure of
human aldose reductase complexed with potent (IC50 = 3nM) inhibitor zo-
polrestat: 3,4-dihydro-4-oxo-3-5-(trifluoromethyl)-2-benzothiazolylmethyl
-1-phtalazineacetic acid provides a picture of multiple hydrophobic contacts
of phtalazineacetic acid moiety lining the active site pocket. By superposi-
tion of chromone ring onto the phtalazineacetic acid part of zopolrestat stru-
cture similar interactions with the enzyme could be achieved. In particular,
our finding that position 3 of the chromone ring requires a bulky hydropho-
bic substituent matches nicely with zopolrestat complex crystal structure in
which trifluoromethyl-2-benzothiazolyl is present at position 3.
In summary, the agreement in description of QSAR in terms of classical
and quantum chemical parameters is good. Flavonoids are in general good
inhibitors of both enzymes, with their inhibitory potency spreading over 5
orders of magnitude. However, there are specific differences in requirements
for their binding to the enzyme sites AR and PTK. For the binding to the en-
zyme site AR (i) a hydrogen bond donor should be present at position 4’ (ii)
larger substituent in 4’ than OH is not favourable (iii) position 3 requires a
bulky hydrophobic substituent .
To the contrary, in PTK (iv) a hydrogen bond donor at position 3' or 4’ in
the phenyl ring is required and (v) specific orientation of hydrophobic sub-
stituent at position 8 is required and steric hindrance at position 3 in the
chromone ring is decreasing the inhibitiory potency of flavonoids.
CONCLUSIONS
Results of our QSAR study in which we applied both classical and quan-
tum chemical computed descriptors could be consistently explained in terms
of physico-chemical nature: hydrophobicity, electronic structure and steric
factors.
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Differences in QSAR of flavonoids between two enzymes PTK and AR
could be translated into specific substituent structural requirements. Spe-
cific differences in inhibition ability towards PTK and aldose reductase for a
large data set of flavonoids comprising a broad variety of substituents pro-
vide one with incentives for rational drug design of novel flavonoid analo-
gues. Work along these lines is in progress in this laboratory.
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PTK – protein tyrosine kinase
ARI – aldose reductase inhibitors
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NADPH – nicotinamide-adenine-dinucleotide phosphate.
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QSAR za flavonoide: 4. Diferencijalna inhibicija aldoza-reduktaze
i p56 proteina tirozin-kinaze
Alenka [tefani~-Petek, Ale{ Krbav~i~ i Tom [olmajer
Flavonoidi su grupa biljnih produkata niske molekularne te`ine, sa zajedni~kim
temeljnim spojem flavonom (2-fenilkromonon), a pokazali su se vrlo dobrima u ra-
znim farmakologijskim primjenama. Uporabom tehnike slu~ajnog odabira uo~eno je
da su flavoni inhibitori aldoza-reduktaze, enzima va`nog pri lije~enju diabeti~kih
komplikacija kao {to je stvaranje katarakte. S druge strane, velik broj prirodnih i
umjetnih flavonoida testirani su kao specifi~ni inhibitori proteina tirozin-kinaze
(PTK). Kineti~ke analize inhibicije PTK pokazuju da su flavonoidi usporedivi inhi-
bitori s nukleotidom ATP. U svrhu razvoja kvantitativnog odnosa strukture i aktiv-
nosti za te enzimske sustave uporabom klasi~nih i kvantnokemijskih deskriptora
provedena je iscrpna analiza dostupnih eksperimentalnih podataka. Ukazano je na
va`nost deskriptora za opis svojstava vezivanja obiju enzimskih receptorskih aktiv-
nih mjesta, a dobiveni rezultati pokazuju koja elektronska kao i hidrofobna i steri-
~ka svojstva supstituenata imaju va`nu ulogu u njihovim pogodovnim vezivanjima.
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